On May 28, 2015, Stonegate Capital Partners released an extensive Equity Research Report on PharmaCyte Biotech, Inc. The firm’s reports are issued to targeted funds, and institutional investors also have access to Stonegate’s research from a variety of services including Bloomberg, Thomson Reuters, Zach’s, Capital IQ, The Markets, Morningstar and FactSet among others. Stonegate has the ability to actively track the institutional investors who access their research.
Stonegate Capital Partners is an investment banking and corporate advisory firm dedicated to serving the specialized needs of small-cap public companies like PharmaCyte Biotech, Inc. For over 40 years, Stonegate has been bringing public companies and institutional investors together, either by virtue of private placements, coordinating block trades, or through open market transactions.
Since the firm’s inception, its mission has been to find innovative, undervalued public companies for its network of leading institutional investors who seek high quality investment opportunities. Stonegate provides a full spectrum of services including equity research, sales and trading, investment banking, and capital markets advisory services.
Stonegate’s robust institutional outreach effort is the foundation of its firm, and a core aspect of the company’s success. This, combined with its team’s extensive institutional relationships and experience with complex capital market issues, creates an unparalleled platform for companies looking to grow their institutional shareholder base and ultimately realize optimal valuation in their stock.
Stonegate is a privately owned firm based in Dallas, Texas, that has built a culture of success and innovation.